Oceania · Markets & Finance · Australian Financial Review

CSL signs drug deal with Swiss biotech giant to fight rare disease

Published by Australian Financial Review · Australia 11 h ago

The Australian pharma giant believes the drug will be an important therapeutic option to improve kidney function.

Read the full article on Australian Financial Review Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.afr.com)

Also worth reading

Business News (WA)

Orbital inks second Indian drone propulsion deal

Has AI Reset the Cycle?

The Trust Trap: why tighter control can hurt a growing business

Property downturn worsens with less than 50pc of auctions leading to a sale

Pavlova hits the Big Apple as Gelato Messina makes New York debut

NZ Herald Business

Fulton Hogan revenues and profits rebound after 2025 downturn